AQST Aquestive Therapeutics, Inc.
8-K Current Report
Filed: March 4, 2026
Health Care
Pharmaceutical PreparationsAquestive Therapeutics, Inc. (AQST) 8-K current report filed with SEC EDGAR on March 4, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items3 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 2.02: Results of Operations and Financial Condition
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 1.01 · Entry into a Material Definitive Agreement
- • Marketing Approval Deadline for RTW Purchase and Sale Agreement extended to June 30, 2027, buying more time for regulatory milestone
- • RTW receives warrant for 375,000 shares at $4.00/share, expiring March 3, 2029 — dilution cost for the extension
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year fiscal 2025 earnings reported; period ended December 31, 2025
- • Full financial details and schedules in Exhibit 99.1 of this 8-K filing
Item 7.01 · Regulation FD Disclosure
- • Aquestive (AQST) releasing updated investor presentation to institutional investors and analysts — potential catalyst for institutional interest
- • Presentation filed as Exhibit 99.2; full content of disclosed information resides there
Other Aquestive Therapeutics, Inc. 8-K Filings
Get deeper insights on Aquestive Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.